ATR and neoplasm: In preclinical breast cancer studies, the combination of a selective ATR inhibitor with Avelumab and platinum-based chemotherapy resulted in antitumor effect in syngeneic tumor models, leading to overall survival benefit compared to any dual-combination group, and also provided protective antitumor immunity with immunological memory in cured mice (131).